Genotyping of the polymorphic N-acetyltransferase (NAT2) and loss of heterozygosity in bladder cancer patients

Clinical Genetics

Volumn 53, Issue 5, 1998, Pages 396-402

  Schnakenberg, E ^a   Ehlers, Chr ^a   Feyerabend, W ^a   Werdin, R ^b   Hubotter R ^b   Dreikorn, K ^b   Schloot, W ^a  

^a UNIVERSITY OF BREMEN   (Germany)

^b Department of Pediatric Surgery   (Germany)

Author keywords

Allele distribution; ASO PCR RFLP genotyping; Bladder cancer; Loss of heterozygosity; N acetyltransferase

Indexed keywords

ACYLTRANSFERASE;

ACETYLATION; ADULT; AGED; ALLELE; ARTICLE; BLADDER CANCER; CANCER RISK; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; GENE LOCUS; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0031777497     PISSN: 00099163     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0004.1998.tb02753.x     Document Type: Article

References (37)

1. Golka K, Bandel T, Urfer W, Bolt HM. Berufliche Risikofaktoren für Tumoren der Harnblase und der Prostata. Dortmund: Bundesanstalt für Arbeitsschutz, 1995.
2. Weber WW. The acetylator genes and drug response. New York: Oxford University Press, 1987.
3. Rehn L. Blasengeschwülste bei Fuchsin-Arbeitern. Arch Klin Chir 1895: 50: 588-600.
4. Kunze E, Chang-Claude J, Frentzel-Beyme R. Life style and occupational risk for bladder cancer in Germany. Cancer 1992: 69: 1776-1790.
5. Cartwright RA, Glasham RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, Kahn MA. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 1982: 2: 842-845.
6. Hein DW. Acetylator genotype and arylamine-induced carcinogenesis. Biochim Biophys Acta 1988: 948: 37-66.
7. Hanssen HP, Agarwal DP, Goedde HW, Bucher H, Huland H, Brachmann W, Ovenbeek R. Association of N-acetyltransferase polymorphism and environmental factors with bladder carcinogenesis. Eur Urol 1985: 11: 263-266.
8. Mommsen S, Barfod NM, Aagard J. N-acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low-risk population. Carcinogenesis 1985: 6: 199-201.
9. Franke S, Klawitz I, Schnakenberg E, Rommel B, van de Ven W, Bullerdiek J, Schloot W. Isolation and mapping of a cosmic clone containing the human NAT2 gene. Biochem Biophys Res Commun 1994: 199: 52-55.
10. Deguchi T, Mashimo M, Suzuki T. Correlations between acetylator phenotypes and genotypes of polymorphic arylarnine N-acetyltransferase in human liver. J Biol Chem 1990: 265: 12757-12760.
11. Ohsako S, Deguchi T. Cloning and expression of cDNAs for polymorphic and monomorphic arylamine N-acetyltranferases from human liver. J Biol Chem 1990: 265: 4630-4634.
12. Blum M, Grant DM, McBride OW, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization and functional expression. DNA Cell Biol 1990: 9: 193-203.
13. Hickman D, Sim E. N-acetyltransferase polymorphism: comparison of phenotype and genotype in humans. Biochem Pharmacol 1991: 42: 1007-1014.
14. Vatsis KP, Weber WW, Bell DA, Dupret J-M, Evans DAP, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T, Yamazoe Y. Nomenclature for N-acetyltransferases. Pharmacogenetics 1995: 5: 1-17.
15. Hermanek P, Scheibe O, Spiessl B, Wagner G. TNM Klassifikation maligner Tumoren, 4th edn. Berlin: Akademie-Verlag, 1989.
16. Lahiri DK, Nurnberger JI. A rapid non-enymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res. 1991: 19: 5444.
17. Grant DM. Molecular genetics of the N-acetyltransferases. Pharmacogenetics 1993: 3: 45-50.
18. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drug and carcinogens in humans. Proc Natl Acad Sci USA 1991: 88: 5237-5241.
19. Hickman D, Risch A, Camilleri JP, Sim E. Genotyping human polymorphic arylamine N-acetyltransferase: identification of new slow allotypic variants. Pharmacogenetics 1992: 2: 17-226.
20. Agúndez JAG, Martínez C, Olivera M, Ledesma MC, Ladero JM, Benítez J. Molecular analysis of the arylamine N-acetyltransferase polymorphism in a Spanish population. Clin Pharmacol Ther 1994: 56: 202-209.
21. Lin HJ, Han CY, Lin BK, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am J Hum Genet 1993: 52: 827-834.
22. Lin HJ, Han CY, Lin BK, Hardy S. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994: 4: 125-134.
23. Rothman N, Hayes RB, Bi W, Caporaso N, Broly F, Woosley RL, Yin S, Feng P, You X, Meyer UA. Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics 1993: 3: 250-255.
24. Mashimo M, Suzuki T, Abe M, Deguchi T. Molecular genotyping of N-acetylation polymorphism to predict phenotype. Hum Genet 1992: 90: 139-143.
25. Bell DA, Taylor JA, Butler MA, Stephens EA, Wiest J, Brubaker LH, Kadlubar FF, Lucier GW. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis 1993: 14: 1689-1692.
26. Ilett KF, Chiswell GM, Spargo RM, Platt E, Minchin RF. Acetylation phenotype and genotype in Aboriginal leprosy patients from the north-west region of Western Australia. Pharmacogenetics 1993: 3: 264-269.
27. Mrozikiewicz PM, Drakoulis N, Roots I. Polymorphic arylarnine N-acetyltransferase (NAT2) genes in children with insulin-dependent diabetes mellitus. Clin Parmacol Ther 1994: 56: 626-634.
28. Deloménie C, Grant DM, Mathelier-Fusade P, Jacomet C, Leynadier F, Jacqz-Aigrain E, Rozenbaum W, Krishnarnoorthy R, Dupret J-M. N-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients. Br J Clin Pharmac. 1994: 38: 581-582.
29. Evans DAP, Eze LC, Whibley EJ. The association of the slow acetylator phenotype with bladder cancer. J Med Genet 1983: 20: 330-333.
30. Ladero JM, Kwok CK, Jara C, Fernandez L, Silmi AM, Tapia D, Uson AC. Hepatic acetylator phenotype in bladder cancer patients. Ann Clin Res 1985: 17: 96-99.
31. Risch A, Wallace DMA, Bathers S, Sim E. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. Hum Mol Genet 1995: 4: 231-236.
32. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated caucasian individuals: correlation with phenotype activity. Am J Hum Genet 1995: 57: 581-592.
33. Hayes RB, Bi W, Rothman N, Broly F, Caporaso N, Feng P, You X, Yin S, Woosley RL, Meyer UA. N-Acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis 1993: 14: 675-678.
34. Kirlin WG, Trinidad A, Yerokun T, Ogolla F, Ferguson RJ, Andrews AF, Brady PK, Hein DW. Polymorphic expression of acetyl coenzyme A-dependent arylamine N-acetyltransferase and acetyl coenzyme A-dependent O-acetyltransferase-mediated activation of N-hydroxyarylammes by human bladder cytosol. Cancer Res 1989: 49: 2448-2454.
35. Land SJ, Zukowski K, Lee M-S, Debiec-Rychter M, King CM, Wang CY. Metabolism of aromatic amines: relationships of N-acetylation, O-acetylation, N,O-acetyltransfer and deacetylation in human liver and urinary bladder. Carcinogenesis 1989: 10: 727-731.
36. Fujiwara Y, Emi M, Ohata H, Kato Y, Nakajima T, Mori T, Nakamura Y. Evidence for the presence of two tumor suppressor genes on chromosome 8p for colorectal carcinoma. Cancer Res 1993: 53: 1172-1174.
37. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. Allelotype of human bladder cancer. Cancer Res 1994: 54: 531-538.